MedTrace Logo

Non-interventional European Study of Trabectedin + PLD in the Treatment of Relapsed Ovarian Cancer (ROC) Patients

NCT02825420 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 220

Last updated 2021-10-29

Study results available
· View outcomes & findings →

Summary

Non-interventional, multicenter, prospective, European study to describe the effectiveness of trabectedin + PLD in the treatment of relapsed ovarian cancer (ROC) patients according to SmPC regardless of previous use of an antiangiogenic drug

Conditions

  • Relapsed Ovarian Cancer

Interventions

DRUG

trabectedin

Sponsors & Collaborators

  • PharmaMar

    lead INDUSTRY

Principal Investigators

  • María José Pontes · PharmaMar

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-07-28
Primary Completion
2019-09-18
Completion
2019-09-18

Countries

  • Belgium
  • France
  • Germany
  • Italy
  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02825420 on ClinicalTrials.gov